Axogen Inc (AXGN)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS

13631 PROGRESS BLVD. ALACHUA, FL 32615

Axogen is a regenerative medicine company with a portfolio of products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. Co.'s product portfolio includes: Avance Nerve Graft, an allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed); AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves; and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

Data as of 2020-08-01
Market Cap452.093 Million Shares Outstanding39.762 Million Avg 30-day Volume529.572 Thousand
P/E Ratio Dividend Yield EPS-0.71
Price/Sales5.582 Price cash flow ratio Price free cash flow ratio-20.9
Book Value3.12 Price to Tangible Book3.7 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.017468
BETA0.481506 52-week High/Low18.84 / 7.16 Stddev0.156746
View SEC Filings from AXGN instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 113 38 (2.49%)
Aggregate 13F shares on 03/31/2020: 32.808 Million 19.648 Million
Aggregate 13F shares on 12/31/2019: 33.316 Million 19.301 Million
Percent change: -1.53% 1.80%
Funds creating new positions: 17 8
Funds Adding to an existing position: 45 15
Funds closing out their position: 24 14
Funds reducing their position: 28 7
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding AXGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AXGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FREITAG GREGORY GENE

0 2020-06-23 4

BLACKFORD QUENTIN S.

  • Director
530,180 2020-06-17 3

COLLERAN LISA N

  • Director
0 2020-06-04 0

RUDELIUS ROBERT JAMES

  • Director
0 2020-06-01 4

GOLD MARK STEPHEN

  • Director
0 2020-06-01 5

NEELS GUIDO J

  • Director
0 2020-06-01 3

WENDELL AMY MCBRIDE

  • Director
0 2020-06-01 3

LEVINE ALAN M

  • Director
0 2020-06-01 3

OTTINGER BRADLEY GENERAL COUNSEL AND CCO

  • Officer
0 2020-06-01 2

DONOVAN MICHAEL PATRICK VP OPERATIONS

  • Officer
43,646 2020-05-28 5

DEVINNEY ERICK WAYNE VP, CLINICAL&TRANSLATIONAL SC

  • Officer
51,056 2020-04-28 4

ZADEREJ KAREN L. CEO

  • Officer
  • Director
658,869 2020-04-16 5

FRIEDMAN MARK LOUIS VP,REGULATORY & QUALITY

  • Officer
0 2020-03-16 3

MARIANI PETER J CHIEF FINANCIAL OFFICER

  • Officer
0 2020-03-16 3

SCOPELIANOS ANGELO VP RESEARCH & DEVELOPMENT

  • Officer
0 2020-03-16 2

BILLET ISABELLE CHIEF STRATEGY AND BD OFFICER

  • Officer
0 2020-03-16 3

MARTINEZ MARIA D. CHIEF HUMAN RESOURCES OFFICER

  • Officer
0 2020-03-16 3

SANDBERG ERIC CHIEF COMMERCIAL OFFICER

  • Officer
0 2020-03-16 2

HANSEN DAVID K VP FINANCE & TREASURER

  • Officer
0 2019-08-21 1

GROOMS JAMIE MARK

  • Director
0 2019-08-14 1

MANDATO JOSEPH M

  • Director
0 2019-05-16 0

GINGRICH JON S. CHIEF COMMERCIAL OFFICER

  • Officer
4,190 2019-02-15 0

MCCARREY SHAWN F SVP SALES

  • Officer
0 2019-01-03 0

LEACH KEVIN VICE PRESIDENT

  • Officer
No longer subject to file 2018-08-17 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
No longer subject to file 2018-07-23 0

ESSEX WOODLANDS FUND IX, L.P.

  • 10% Owner
3,711,111 2017-11-20 0

ENGELS JOHN P VP

  • Officer
No longer subject to file 2017-06-08 0

ESSEX WOODLANDS FUND IX, L.P.

ESSEX WOODLANDS FUND IX-GP, L.P.

ESSEX WOODLANDS IX, LLC

  • 10% Owner
4,861,111 2015-08-26 0

JOHNSTON LEE ROBERT JR CHIEF FINACIAL OFFICER

  • Officer
25,000 2015-06-02 0

SCHIAPARELLI JILL F CHIEF MARKETING OFFICER

  • Officer
0 2014-12-29 0

HARPER JOHN FREDERICK

  • Director
0 2014-01-02 0

HOPFENSPIRGER LARRY

  • Director
  • 10% Owner
0 2012-11-12 0

HEDGER BRADLEY JAY VICE PRESIDENT, SALES

  • Officer
0 2011-12-16 0

DE NOVO VENTURES II, L.P.

DE NOVO MANAGEMENT II, L.L.C.

  • 10% Owner
1,426,392 2011-09-30 0

SALOVICH ELMER

  • Director
100,000 2011-02-18 0

HELLERVIK LOWELL WALDO

  • Director
15,500 2011-01-26 0

BRINK SANFORD M

  • Director
345,280 2010-11-01 0

HEANEY TIMOTHY MICHAEL

  • Director
0 2010-11-01 0

WORMS-LYNCH KEVIN CHRISTOPHER

  • Director
0 2010-11-01 0

PERIAKARUPPAN RAMANATHAN

  • Director
219,363 2010-02-09 0

BERLIN JUDD A

  • Director
0 2008-09-26 0

SIGG DANIEL C

  • Director
0 2008-09-26 0

ROLLWAGEN C ANDREW

  • Director
0 2008-09-26 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments